SHANGHAI, March 29, 2017 /PRNewswire/ -- WuXi Biologics, a leading open-access R&D capability and technology platform
Asia-Pacific Bioprocessing Excellence Awards aims
As an open-access biologics technology platform, WuXi Biologics opened its state-of-the-art biologics manufacturing facilities at Wuxi city in 2012, which isáthe first ináChinaáthat met cGMP standards ofáthe United States, theáEuropean Union, andáChina. In 2015, WuXi began construction of world's largest mammalian cell culture manufacturing facility using disposable bioreactors with a planned manufacturing capacity of 30000L, and completed construction of Asia's largest perfusion biologics manufacturing facility using disposable bioreactors in 2016, offering end-to-end solution to our worldwide customers and partners.
"WuXi Biologics is honored to be recognized by IMAPAC," said Dr. Chris Chen, CEO of WuXi Biologics, "The award truly reflects all of the efforts we have put forth to provide our customers with high-quality and best-in-class service to help accelerate biologics development from concept to commercialization."
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."á Please visit http://www.wuxiapptec.com
About WuXi Biologics
WuXi Biologics, a WuXi AppTec Affiliate, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi's Biologics services, please visit:http://www.wuxibiologics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-biologics-receives-asia-pacific-best-bioprocessing-excellence-award-from-imapac-300431576.html
SOURCE WuXi AppTec
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All